Results 51 to 60 of about 1,653 (153)

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph ...
Kazuma Soya, Takeru Fujimoto, Yu Osaki, Koji Matsumoto, Yusuke Takei, Yoshio Sugino, Tsutomu Maruta, Hiroshi Iwamura   +7 more
wiley   +1 more source

Radioiodine‐Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy

Cancer Innovation, Volume 5, Issue 4, August 2026.
Radioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Yamin Li, Zuoxiang He
wiley   +1 more source

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma

Advances in Radiation Oncology, 2021
Purpose: Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity.
Jonathan E. Schoenhals, BS, Osama Mohamad, MD, PhD, Alana Christie, MS, Yuanyuan Zhang, MD, PhD, Daniel Li, MD, Nirmish Singla, MD, MSCS, Isaac Bowman, MD, Waddah Arafat, MD, Hans Hammers, MD, Kevin Courtney, MD, PhD, Suzanne Cole, MD, Aditya Bagrodia, MD, Vitaly Margulis, MD, Neil Desai, MD, Aurelie Garant, MD, Hak Choy, MD, Robert Timmerman, MD, James Brugarolas, MD, PhD, Raquibul Hannan, MD, PhD   +18 more
doaj   +1 more source

Stereotactic radiotherapy to oligoprogressive lesions detected with ⁶⁸Ga-PSMA-PET/CT in castration-resistant prostate cancer patients.

, 2021
Purpose We assessed the outcomes of stereotactic body radiotherapy (SBRT) to treat oligoprogressive castration-resistant prostate cancer (CRPC) patients with
Tilki, BURAK, Hurmuz, Pervin, Guler, Ozan Cem, Akyol, Fadil, Ozyigit, Gokhan, Oymak, Ezgi, Onal, Cem   +6 more
core   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, Volume 10, Issue 2, Page 184-191, June 2026.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade

Cancer Treatment and Research Communications, 2020
Background: While the concept of oligometastatic disease is increasingly recognized as a distinct clinical disease state, the concept of oligoprogression is less well-characterized.
Kunal K. Sindhu, Amanda Leiter, Erin Moshier, Jung-Yi Lin, Emily Carroll, Danielle Brooks, Jennifer Ben Shimol, Elliot Eisenberg, Emily J. Gallagher, Richard G. Stock, Matthew D. Galsky, Michael Buckstein   +11 more
doaj   +1 more source

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

BMC Cancer, 2021
Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce.
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano, Ryota Kominami, Keisuke Tomii, Hidekazu Suzuki, Tomonori Hirashima, Satoshi Tanaka, Junji Uchida, Mitsunori Morita, Masaki Kanazu, Masahide Mori, Kenji Nagata, Ikue Fukuda, Motohiro Tamiya   +21 more
doaj   +1 more source

First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam

Thoracic Cancer, Volume 17, Issue 12, June 2026.
Alectinib demonstrated superior intracranial disease control and systemic efficacy compared with ceritinib in Vietnamese patients with ALK‐positive NSCLC and brain metastases. Upfront brain radiotherapy appeared to provide greater benefit when combined with ceritinib than with alectinib (exploratory, interaction p > 0.6).
Hoang Gia Nguyen, Xuan Hau Nguyen, Phuong Nguyen, Thu Huong Nguyen, Quang Bui Vinh   +4 more
wiley   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

sj-jpg-1-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

, 2023
Supplemental material, sj-jpg-1-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun ...
Yongfeng Yu (5883800), Lan Shen (381473), Huayan Huang (8067056), Ziming Li (402892), Wendi Xuzhang (14719390), Shun Lu (402894)   +5 more
core   +1 more source